EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung

Chia-Yu Kuo iD, Ming-Ju Tsai iD, Jen-Yu Hung, Mei-Hsuan Lee, Kuan-Li Wu iD, Yu-Chen Tsai, Cheng-Hao Chuang iD, Chung-Wen Huang, Chin-Ling Chen, Chih-Jen Yang iD, Inn-Wen Chong

The Kaohsiung Journal of Medical Sciences · 2024

DOI: 10.1002/kjm2.12822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2024. Verfasst von Chia-Yu Kuo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical Universit…. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ramucirumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an anti‐ vascular endothelial growth factor (VEGF) agent, bevacizumab or ramucirumab, is indicated for advanced lung adenocarcinoma harboring EGFR mutation. This study aimed to show the real‐world data of combination therapy and compare the effectiveness between bevacizumab and ramucirumab in combination with an EGFR‐TKI. This retrospective study enrolled 47 patients diagnosed of stage IV lung adenocarcinoma with exon 19 deletion or L858R point mutation, receiving a first‐line EGFR‐TKI with anti‐VEGF agent, including 34 (72%) and 13 (28%) patients receiving bevacizumab and ramucirumab, respectively. The response rate was similar in both groups ( p = 0.38). Patients receiving bevacizumab had similar progression free survival (PFS) as those receiving ramucirumab (median PFS: 21.9 vs. 24.2 months, p = 0.4871); similar finding was noted in overall survival (OS) (median OS: 33.5 months vs. not reached, p = 0.4618). Patients receiving ramucirumab experienced a significantly high‐grade hypertension compared to those receiving bevacizumab ( p = 0.0351). Multivariable Cox regression analysis found independent risk factors for worse PFS included poorer ECOG performance status, multiple (≥3) metastatic sites, brain metastasis, and pleural metastasis/effusion, while the type of anti‐VEGF agent was not a risk factor. Pericardial metastasis/effusion was the only one independent risk factor for worse OS. In summary, ramucirumab may have similar effectiveness as bevacizumab in combination with an EGFR‐TKI as first line therapy for advanced lung adenocarcinoma harboring susceptible EGFR mutation. Further large‐scale registry‐based cohort studies may be needed to validate our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabCarcinoma, Non-Small-Cell LungLung NeoplasmsRamucirumabTyrosine Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdenocarcinoma of LungAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsMutationNeoplasm StagingRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

epidermal growth factor receptorlung adenocarcinomatyrosine kinase inhibitorvascular endothelial growth factor

Substanzen

Antibodies, Monoclonal, HumanizedBevacizumabEGFR protein, humanErbB ReceptorsRamucirumabTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.
  • School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Chia-Yu Kuo, Ming-Ju Tsai, Kuan-Li Wu, Cheng-Hao Chuang, Chih-Jen Yang

Zitieren

APA

Kuo, C. Y., Tsai, M. J., Hung, J. Y., Lee, M. H., Wu, K. L., Tsai, Y. C., Chuang, C. H., Huang, C. W., Chen, C. L., Yang, C. J., & Chong, I. W. (2024). Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12822

Vancouver

Kuo CY, Tsai MJ, Hung JY, Lee MH, Wu KL, Tsai YC, et al. Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung. The Kaohsiung Journal of Medical Sciences. 2024. doi:10.1002/kjm2.12822

BibTeX
@article{Kuo2024,
  author = {Kuo, Chia-Yu and Tsai, Ming-Ju and Hung, Jen-Yu and Lee, Mei-Hsuan and Wu, Kuan-Li and Tsai, Yu-Chen and Chuang, Cheng-Hao and Huang, Chung-Wen and Chen, Chin-Ling and Yang, Chih-Jen and Chong, Inn-Wen},
  title = {Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2024},
  doi = {10.1002/kjm2.12822}
}
Kostenlos starten →